miércoles, 18 de noviembre de 2026

AI-based analysis offers new roadmap for precision oncology The new approach combined digital pathology with spatial proteomics to uncover the secrets of metastasis and personalized treatment options. Written byAllison Whitten, PhD

AI-based analysis offers new roadmap for precision oncology The new approach combined digital pathology with spatial proteomics to uncover the secrets of metastasis and personalized treatment options. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/ai-based-analysis-offers-new-roadmap-for-precision-oncology-17460?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8LIehaN3cuMKhf44TpuDaCIzGuw3LCMND0KegpmAAT284K8D3j5Pvo7CQMKvIPDKutXUaS8XSMkC4bvyU0MClaeq4EOQ&_hsmi=449776666&utm_content=449776666&utm_source=hs_email How and why a tumor metastasizes — when a seemingly similar tumor doesn’t — remains one of the biggest questions in cancer research. New research from György Marko-Varga’s lab at Lund University with Istvan Nemeth at the Szeged Clinical hospital, and Peter Horvath’s team at HUN-REN Biological Research Centre suggests a new way to chip away at this question with the help of AI combined with spatial proteomics to reveal the single-cell dynamics of different populations of cancer cells within the same tumor. Their approach offers a promising step up over traditional molecular analyses that view the entire tissue sample at once and miss the functional differences in how different cell types behave. In their case report of a young woman with metastasized melanoma, the researchers identified two spatially distinct tumor cell populations in the original tumor. One, PT1, was an aggressive melanoma subtype that likely drove metastasis into the lungs and eventually the brain. Their analysis also surfaced metabolic and kinase programs associated with the progression and treatment resistance, which suggested that targeted therapies may not work well for the patient, with metabolic inhibitors potentially offering greater gains for the patient. “These findings demonstrate the potential of patient-specific AI-imaging interfaced with proteomic tumor mapping to move beyond conventional pathology, reveal actionable vulnerabilities, and guide more precise combination treatment strategies for advanced melanoma,” Marko-Varga told DDN.

No hay comentarios:

Publicar un comentario